Eptifibatide, a platelet glycoprotein IIb/IIIa inhibitor substantially reduces ischemic complications in coronary stent interventions and could become a routine pre-treatment in stent coronary ...
"The amount of data obtained are overwhelming and will need careful interpretation due to the study's significant implications, which may change the way adjuvant anticoagulation is given to ACS ...
Information from a large database supported the use of GP IIb/IIIa-receptor inhibitors in patients with AMI undergoing PCI. Treatment with abciximab was associated with favorable differences in ...
RUC-4 (CeleCor Therapeutics), an investigational glycoprotein IIb/IIIa inhibitor (GPI) administered by subcutaneous injection, provides rapid and powerful platelet inhibition in patients with STEMI, ...
In patients with stroke and patent large and medium-sized cerebral vessels, the glycoprotein IIb/IIIa receptor inhibitor tirofiban resulted in a greater likelihood of an excellent outcome than ...
NEW ORLEANS -- Patients experiencing major heart attacks had a lower risk of serious complications if they received a single injection of the investigational drug zalunfiban at first medical contact, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results